$30.00
+0.99 (+3.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AVBP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 10 tracked-famous managers (HHLR ADVISORS, LTD., D. E. Shaw & Co., Inc., Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., +5 more) · FINRA short interest 13.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997Progression Free Survival (PFS) determined by blinded independent central review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice | Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations | 480 | Feb 2029 | ≤ 924 d | 2026-08-03 |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsNCT07066657Dose Limiting Toxicity (DLT) - Phase IaNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: MRG007, MRG007 and Bevacizumab | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | 572 | Mar 2028 | ≤ 590 d | 2026-08-13 |
| Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.NCT07755436Treatment-Emergent Adverse Event (TEAE)Open-label · Treatment | Phase 1 | Recruiting | Drug: ARR-002 | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic Endometrial Cancer | 180 | Aug 2027 | ≤ 377 d | 2026-08-10 |
| Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550Progression Free Survival (PFS) determined by blinded independent central review (BICR)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy | Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations | 398 | 2025-08-15 | — | 2025-06-22 |
| Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsNCT05364073Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of FurmonertinibNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Furmonertinib, Furmonertinib, Furmonertinib, Furmonertinib, Furmonertinib | Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I | 160 | 2025-06-03actual | — | 2026-03-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19